MYOZ3

Across TCGA pan-cancer cohorts, MYOZ3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYOZ3 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MYOZ3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYOZ3 expression acts as an unfavorable survival marker.

KIRP and LUSC are the cancer types where MYOZ3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.105	0.688	.004	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYOZ3–KIRP (OS)

Open the KIRP breakdown →